Demand for AI, VR driving OR technology market toward $7B

The U.S. and European market for operating-room (OR) equipment and technology will grow from $4.5 billion now to more than $7 billion by 2022. Hospitals hoping to keep up with their competition during the boomlet need to invest in integrating robotics to improve precision, virtual reality to inform pre-surgery planning and AI to analyze risks.

So says Frost & Sullivan in new market research it began promoting June 27.

Other key components of winning strategies will include partnering with industry to reach a broader patient base and providing patient-centric services that “are not necessarily aligned to clinical outcomes,” Frost & Sullivan says.

A senior analyst with the company adds that, by 2022, some 35% to 45% of ORs worldwide will become integrated ORs.

“Approximately $30 billion worth of integration opportunities are likely to become available to healthcare and non-healthcare companies by this period when ORs make the transition from regular rooms to an integrated environment,” says the analyst, Bejoy Daniel.

Frost & Sullivan says the OR services segment is highly fragmented and has more potential in Europe than the United States. Still, around 70% to 75% of major hospitals have adopted OR management solutions across both geographic regions.

“The OR is transforming from a seemingly simple box into a technology-powered, infection-free and sleek surgical environment,” the company says.

Dave Pearson

Dave P. has worked in journalism, marketing and public relations for more than 30 years, frequently concentrating on hospitals, healthcare technology and Catholic communications. He has also specialized in fundraising communications, ghostwriting for CEOs of local, national and global charities, nonprofits and foundations.

Around the web

The tirzepatide shortage that first began in 2022 has been resolved. Drug companies distributing compounded versions of the popular drug now have two to three more months to distribute their remaining supply.

The 24 members of the House Task Force on AI—12 reps from each party—have posted a 253-page report detailing their bipartisan vision for encouraging innovation while minimizing risks. 

Merck sent Hansoh Pharma, a Chinese biopharmaceutical company, an upfront payment of $112 million to license a new investigational GLP-1 receptor agonist. There could be many more payments to come if certain milestones are met.